Top British American Tobacco investor Woodford says backs Reynolds deal
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
People walk past the British American Tobacco offices in London, Britain October 21, 2016. REUTERS/Stefan Wermuth
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
LONDON (Reuters) - Leading British investor Neil Woodford's fund firm said on Thursday it backed a takeover of Reynolds American (NYSE: RAI) by British American Tobacco (NYSE: BATS), calling the tie-up "inevitable".
The firm's 9.4 billion pound ($11.71 billion) Equity Income Fund, which faced a "challenging October", used a spike in Reynolds' share price to sell out of that firm and reinvested some of the proceeds in its position in BAT.
"Our view is that this deal was inevitable and, although it has happened earlier than we thought, makes a lot of strategic and financial sense. We will be voting in favor of the transaction," the fund said in an update on the firm's website.
The fund was the 7th biggest investor in BAT at the end of July, Thomson Reuters data showed. At the end of October, it had 6.25 percent of its assets invested in the company, Woodford said.
Woodford's view on the deal echoes that of Citi analysts which saw the Reynolds' rejection as a formality and expected the firms to agree on terms next month.
Also in October, Woodford said the fund had sold its position in Swiss pharmaceutical firm Roche (NYSE: ROG), to use the money to increase its investments in other companies including Capita (NYSE: CPI) and Paypoint
At the end of September, Woodford had been the 30th biggest investor in Roche, Thomson Reuters data showed.
The fund lost 1.44 percent in October, the firm said on its website, but remained up 2.4 percent in the year-to-date, with its largest positions in GlaxoSmithKline (NYSE: GSK) and Imperial Brands (NYSE: IMB).
(Reporting by Simon Jessop, editing by Vikram Subhedar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ladder Capital (LADR) to Explore Sale - Reuters
- Sense of duty draws U.S. veterans to Dakota pipeline protest
- Colombia's ELN says peace talks will begin once rebels freed
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!